Year: 2026
Type: article
Abstract: A phase 3 trial of rituximab vs ocrelizumab in newly diagnosed relapsing-remitting MS gave a remarkably diplomatic result.Rituximab was non-inferior to ocrelizumab in suppressing MRI disease activity between 6 and 24 months.Relapse, disability and cognitive outcomes were similar, although analyses were underpowered to exclude clinically important differences.The separation came with infection rates: 82% with rituximab vs 69% with ocrelizumab.Most were mild, but with no long-term safety data.However, rituximab's lower acquisition cost looks different when including recurrent infections.Patients might end up paying the difference in coughs and antibiotics.
Source: Practical Neurology
Author: A Fo Ben
Language: English
Subfield: Clinical Neurology
Field: Medicine
Domain: Health Sciences
Open Access status: bronze
OpenAlex ID: W7226016813
